Our Chief Business Officer Guillaume Demarne attends the 5th Gene Therapy for Ophthalmic Disorders Summit in Boston, Sept. 10-12, 2024.

Testing and evaluating the safety and efficacy of ocular gene therapies has become a significant part of Experimentica’s expertise and business over the years. Book a meeting during the summit to discuss our in vitro, in vivo, histology/immunohistochemistry, and quantification & characterization capabilities.

Find out more

Wet AMD models
Dry AMD models
Glaucoma models
PK studies
Tox studies
Animal welfare at Experimentica